Use of Exenatide and Pramlintide to Decrease Post-prandial Hyperglycemia

Completed · Phase 4

Conditions studied: Type 1 Diabetes

In brief

The main purpose of the study is to determine the effects of 16 weeks of adjunctive pramlintide or exenatide use on glycemic control in Type 1 Diabetes.

Key facts

Study ID

NCT01269047

Run by

Albert Einstein College of Medicine

People needed

37

Starts

2009-08-01

Expected to finish

2016-12-01

Last updated by the study team

2018-04-12

Who can join

Age: 12 and older, up to 21. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Age of 12 to 21 years.
• HbA1C less than 9%
• Subjects must be on intensive insulin management
• Tanner stage greater than or equal to 3
• Having Type 1 Diabetes for at least one year
• Type 1Diabetes defined by ADA criteria and having at least one of the following antibodies a. Anti-GAD (glutamic acid decarboxylase) b. Anti-islet cell 512 (ICA512) c. Anti-insulin
• Willing to give consent.

You may not qualify if…

• Type 2 diabetes.
• Having any other chronic condition except hypothyroidism stable on medications.
• On chronic medications that may affect glucose excursions.
• Anemia as defined as Hb less than 9 gm/dl.
• Abnormal amylase, lipase or creatinine (twice normal).
• Abnormal Liver function tests(three times above normal)
• Unsupportive family environment as determined by clinicians and/or social workers.
• Pregnant or lactating mothers

Where it is running

• Albert Einstein College of Medicine West Campus Clinical Research Center — The Bronx, New York, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.